Despite consistent recommendations and growing clinical evidence, uptake of SGLT2i and GLP1 RA therapies in people with type 2 diabetes and cardiorenal comorbidities has been slow. There is also relatively little research on ethnic differences in those starting second-line therapy. This is an omission, as ethnic minority groups have higher rates of morbidity and mortality associated with type 2 diabetes.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Chronic cough
Differential diagnostic detective work and trial therapies
- Lavender oil preparation: long-term use and use in adolescents
New database analysis closes important knowledge gaps
- Case Report
An unusual reason for gastrointestinal bleeding
- Axial spondyloarthritis
Sacroilitis on MRI and/or X-ray as a decisive criterion
- Postoperative cognitive dysfunction
Effects of midazolam and dexmedetomidine
- From symptom to diagnosis
Abdominal pain – groin pain: musculoskeletal causes
- Immunotherapy
Subcutaneously or intravenously?
- Cannabis - medical vs. non-medical use